Wikipedia -WSS

Wikipedia

author：focus 2025-10-01 00:52:22 - browse：55282

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： India sets sights on home

Wikipedia

entertainment

WSS

Feng Zhang, Grail founder join forces on new gene editing startup

Why some people catch Covid but never get sick

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Medical experts are missing from AI regulatory conversations

UCB departs biotech trade group BIO

Seattle police shoot person suspected in downtown stabbing

focus

Wikipedia

focus

Continuity nursing helped my family in our darkest PICU moments

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

How to save PrEP access — and even expand it

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

United colonoscopy coverage change 'may cost lives,' doctors say

U.K. sequencing study surfaces new findings about tumor DNA

Malaria cases in Florida and Texas: Here’s what you need to know

Why the Crimean Bridge is key to Russia's war in Ukraine

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why the Crimean Bridge is key to Russia's war in Ukraine

explore

Why some people catch Covid but never get sick

UCB departs biotech trade group BIO

GSK Flovent asthma inhalers replaced by authorized generics

3 trends to watch in health tech's hiring outlook for 2024

Ahead of JPM, here's who's profiting most in health care

AdventHealth escalates lawsuit against insurance vendor Multiplan

Wikipedia

entertainment

entertainment

leisure time